NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$118.67 -2.85 (-2.35 %)
(As of 06/19/2018 01:22 AM ET)
Previous Close$121.52
Today's Range$117.2950 - $120.50
52-Week Range$102.10 - $149.34
Volume1.28 million shs
Average Volume1.98 million shs
Market Capitalization$27.04 billion
P/E Ratio23.00
Dividend YieldN/A
Beta1.11
Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Debt-to-Equity Ratio0.33
Current Ratio3.35
Quick Ratio2.86

Price-To-Earnings

Trailing P/E Ratio23.00
Forward P/E Ratio18.90
P/E Growth1.09

Sales & Book Value

Annual Sales$3.55 billion
Price / Sales7.44
Cash Flow$7.8434 per share
Price / Cash15.13
Book Value$39.81 per share
Price / Book2.98

Profitability

EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins14.46%
Return on Equity13.70%
Return on Assets9.00%

Miscellaneous

Employees2,525
Outstanding Shares222,500,000

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals declared that its board has initiated a stock buyback plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board believes its shares are undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals (NASDAQ:ALXN) issued its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to analyst estimates of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.38 EPS. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for ALXN?

18 analysts have issued 1-year price objectives for Alexion Pharmaceuticals' shares. Their forecasts range from $130.00 to $180.00. On average, they expect Alexion Pharmaceuticals' share price to reach $160.1111 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.

What are Wall Street analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alexion beat on both earnings and sales in the first quarter of 2018 driven by strength of blockbuster drug Soliris which continues to perform well. The FDA approval for the generalized myasthenia gravis indication has boosted sales further. The prospects of ALXN1210 looks good too given the positive data from the switch study and in treatment-naïve patients. The increase in guidance was also encouraging. Meanwhile, Alexion is looking to diversify its portfolio and reduce its dependence on Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease. Shares of the company have performed better than the industry in the last six months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also imapct sales." (5/2/2018)
  • 2. JPMorgan Chase & Co. analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 55)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
  • Ms. Julie O'Neill MBA, Exec. VP of Global Operations (Age 62)
  • Mr. John B. Moriarty Jr., Former Exec. VP & Gen. Counsel (Age 50)
  • Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)

Has Alexion Pharmaceuticals been receiving favorable news coverage?

Press coverage about ALXN stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.03%), Northern Trust Corp (1.28%), Franklin Resources Inc. (1.00%), BB Biotech AG (0.63%), Wells Fargo & Company MN (0.59%) and Eaton Vance Management (0.52%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Amundi Pioneer Asset Management Inc., State of Tennessee Treasury Department, Franklin Resources Inc., American Century Companies Inc., Federated Investors Inc. PA, Prudential Financial Inc. and Nuveen Asset Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, PointState Capital LP, Redmile Group LLC, Westfield Capital Management Co. LP, FIL Ltd, Braun Stacey Associates Inc., Wells Fargo & Company MN and SG Americas Securities LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $118.67.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $27.04 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.


MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  937 (Vote Outperform)
Underperform Votes:  495 (Vote Underperform)
Total Votes:  1,432
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.